The street drug supply has become a moving target. Just as naloxone distribution reached a kind of critical mass—California selling generic nasal spray online for $24, airlines stocking it in overhead bins—the chemistry changed. Xylazine, a veterinary sedative never meant for human use, started showing up in toxicology reports. Then medetomidine. These adulterants don't respond to opioid antagonists, which means the standard rescue medication can leave someone still not breathing.
That gap is what drew $8 million in federal funding to a Swedish pharmaceutical company most Americans have never heard of. Orexo's September 2025 award from the Biomedical Advanced Research and Development Authority represents the opening tranche of a contract potentially worth $50.9 million—and it's a bet on powder.
Not liquid nasal spray, which already exists in multiple forms. Powder. Specifically, an engineered composite of drug molecules, carriers, and excipients that can sit on a shelf without refrigeration for years, then dissolve within seconds on nasal mucosa to flood the bloodstream faster than an intramuscular injection. BARDA's money will fund toxicology work, clinical trials, manufacturing scale-up, and regulatory filings for OX390, a new chemical entity designed to reverse the respiratory depression that naloxone can't touch. Orexo keeps the commercial rights.
The strategic signal matters as much as the dollars. Federal health agencies increasingly view powder-based intranasal delivery as more than a formulation curiosity—it's emergency infrastructure. And if the technology works for overdose countermeasures, the implications reach well beyond rescue medicine.
The Technology Underneath
AmorphOX, Orexo's proprietary platform, isn't limited to one drug or one crisis. The same particle-engineering approach underpins the company's pipeline candidate for anaphylaxis—OX640, an intranasal epinephrine powder—and its high-dose naloxone formulation, OX124, which received a Complete Response Letter from the FDA in July 2024. Not a rejection, but a request for more human-factors data and technical refinements. The kind of regulatory speed bump that signals efficacy isn't the problem; device usability is.
What catches attention in Orexo's investor materials is the stability data. The company has reported accelerated aging results showing naloxone degradation of 0.1 percent or less at 24 months under conditions that would destroy most pharmaceutical formulations—40°C, 75 percent relative humidity. Epinephrine held to the same standard. Even biologics: spike-protein activity retained, live-virus titer maintained, freeze-thaw cycles survived.
If those claims hold at commercial scale—and that's still an if—the technology could reshape how vaccines and biologics reach populations where cold chain doesn't exist or routinely fails. A 2021 UNICEF analysis of COVID-19 vaccine logistics across 92 countries laid bare just how much of the world's health infrastructure is held hostage by refrigeration requirements. Powder formulations that remain potent at room temperature for years don't just reduce waste. They change the economics of global immunization.
But first, Orexo has to prove the concept in emergency medicine, where speed and simplicity matter more than elegance.
A Market Taking Shape
Intranasal drug delivery is hardly new—allergy sufferers have been using nasal sprays for decades—but powders occupy a narrower, technically demanding slice of the market. Grand View Research pegs the global nasal drug delivery technology market at $76.9 billion in 2023, projecting growth to around $127 billion by 2030. That's a broad bucket: decongestants, migraine treatments, CNS drugs, everything that goes up the nose.
Precedence Research narrows the focus to intranasal drug-delivery devices in the U.S., estimating that segment at roughly $510 million in 2024 and forecasting approximately $1.23 billion by 2034. Powders represent a subsegment within those figures, and methodology varies enough among market-research firms that the numbers should be read as directional rather than gospel.
What's concrete is regulatory momentum. The FDA approved ARS Pharma's neffy—an intranasal epinephrine spray for anaphylaxis—in August 2024 for patients 30 kg and above, then cleared a pediatric dose seven months later for patients 15 to under 30 kg. First needle-free epinephrine product to reach market. ARS has since expanded payer coverage and launched direct-to-consumer campaigns, validating that demand exists for alternatives to auto-injectors.
On the overdose front, Emergent BioSolutions distributed approximately 22 million doses of its over-the-counter Narcan 4 mg nasal spray across the U.S. and Canada in 2023. California launched low-cost state-branded generic naloxone online in April 2025. Hikma's Kloxxado 8 mg partnered with Emergent in January 2025 to consolidate portfolio reach. Indivior's OPVEE (nalmefene) secured approval in May 2023, though a New York Attorney General settlement in September 2025 restricted certain promotional claims and the company ceased promotion in that state.
Powder formulations have been slower to break through. But the pipeline is filling.
Orexo's OX124 was submitted as a New Drug Application and accepted by the FDA in November 2023, with a July 2024 target date for decision. The Complete Response Letter requested human-factors and additional technical data without challenging clinical efficacy—the regulatory equivalent of "show us you can make this device foolproof for a panicked bystander." Orexo completed a new human-factors study and has been working toward resubmission.
Nasus Pharma announced positive interim Phase 2 data in January 2026 for NS002, its intranasal epinephrine powder, showing faster early exposure versus EpiPen. The company uses Aptar's Unidose powder device. OptiNose's Exhalation Delivery System supports both powders and liquids and previously secured U.S. approval for Onzetra Xsail, a sumatriptan powder for migraine, via out-licensing in 2016.
The category is no longer theoretical.
Why Powder Matters
Speed of absorption is the headline advantage, and in emergency medicine, headlines sometimes translate directly to survival rates.
Orexo's OX640 epinephrine data, presented at the European Academy of Allergy and Clinical Immunology meeting in 2025, showed the powder formulation achieved clinically relevant plasma levels faster than intramuscular injection—even under induced allergic rhinitis, a condition that might theoretically impair nasal absorption. Nasus Pharma's NS002 interim results echoed that finding. In anaphylaxis or overdose scenarios, where minutes separate effective intervention from irreversible harm, earlier drug exposure isn't a marginal improvement. It's the point.
A 2019 exploratory study by Orexo demonstrated higher early naloxone exposure for powder formulations compared to Narcan 4 mg. The pivotal OX124-002 trial showed faster absorption versus an intramuscular comparator. Whether that translates to measurably better clinical outcomes—fewer deaths, less neurological damage—remains to be proven in broader populations. But the pharmacokinetic performance is real.
The mechanism stems from particle engineering. AmorphOX generates amorphous composites of drug, carriers, and excipients—sometimes including permeability enhancers—that dissolve rapidly on nasal mucosa. Academic studies published in 2024 and 2025 in the European Journal of Pharmaceutics and Biopharmaceutics and the Journal of Pharmaceutical Investigation confirmed rapid systemic absorption for model amorphous nasal powders, with correlations observed between in vitro release, ex vivo permeation, and in vivo pharmacokinetics for selected formulations.
The amorphous state typically increases solubility and dissolution rate compared to crystalline forms—a principle widely applied in oral solid dispersions. Forty-eight amorphous solid dispersion drug products received FDA approval between 2012 and 2023, according to a 2024 review, so the industry knows how to handle the chemistry. The challenge is translating that expertise from oral tablets to nasal devices.
Thermostability is the second major driver, and this is where the implications extend beyond emergency medicine. Cold-chain logistics account for a meaningful share of vaccine program costs and waste risk. Orexo has reported room-temperature stability data for peptides—cetrorelix at 0.6 percent degradation over 12 months at 40°C/75 percent relative humidity—and biologics. Spike protein retaining activity after three months. Live attenuated virus retaining titer and proving freeze-thaw-resilient.
Independent research on vacuum-foam-dried Newcastle disease virus, thermostable tetanus-diphtheria, and spray-dried nasal COVID candidates—all at various development stages—suggests the technology space is maturing. Perhaps faster than many investors realize.
If powder formulations can eliminate cold-chain requirements for high-value biologics, the commercial and public-health calculus shifts. Meaningfully.
Needle-free administration matters in community settings, though it introduces its own complexities. Layperson use of auto-injectors involves fine-motor coordination under stress, and human-factors studies show that critical errors occur with inhalers and dry-powder inhalers despite training. The FDA's guidance on early development considerations for innovative combination products emphasizes that device usability must be validated—and Complete Response Letters can request human-factors or technical data without requiring new clinical efficacy trials. Exactly what happened with Orexo's OX124.
Intranasal powders avoid injection entirely, but they bring their own usability challenges: dose uniformity, device actuation reliability, patient tolerance. A 2025 article in AAPS PharmSciTech noted that taste, bitterness, and overall user experience impact adherence and real-world effectiveness for nasal products. You can engineer the perfect particle, but if people won't use the device or gag on the sensation, the pharmacokinetics don't matter.
Inside Orexo's Bet
The company provides a useful case study in platform-based drug development—and in the distance between laboratory promise and commercial reality.
Orexo, listed on Nasdaq Stockholm with ADRs trading over-the-counter in the U.S. under ticker ORXOY, has 30 years of formulation experience and roughly 110 employees. Not a startup, not a giant. Its 2024 net sales were 590 million Swedish kronor, with Zubsolv, an opioid-use-disorder treatment, as its commercial product. CEO Nikolaj Sørensen has emphasized in earnings calls that Orexo holds "the world's leading nasal powder delivery" technology and that the BARDA grant strategically de-risks OX390 while validating the platform for broader use.
OX390 represents the newest and most ambitious program. Chief Medical Officer Edward Kim, in a December 2025 interview, framed the candidate as addressing "adulterant-driven respiratory depression unresponsive to antagonists." The molecule is a new chemical entity, not a repurposed opioid antagonist, and it targets the gap created by xylazine and medetomidine in the street supply.
Marshall University researchers published preclinical data in 2025 showing that atipamezole plus naloxone improved outcomes in a rat model of fentanyl-xylazine overdose, suggesting antagonist combinations may ultimately be needed. OX390's mechanism hasn't been fully disclosed, but BARDA's willingness to fund toxicology, clinical development, manufacturing, and regulatory work through a staged contract implies federal interest in non-antagonist countermeasures.
The $8 million first stage is modest. The total $50.9 million contract value, contingent on milestones, signals long-term commitment—or at least long-term concern about the evolving threat.
OX640, the epinephrine powder, is further along scientifically. Positive Phase 1 topline data released in January 2025 showed rapid achievement of target plasma levels, and the product performed faster than intramuscular injection even in subjects with induced allergic rhinitis. Orexo presented additional data at the EAACI 2025 congress, and pharmacodynamic effects—blood pressure and heart rate changes consistent with anaphylaxis treatment—matched pharmacokinetic findings.
Robert Rönn, Orexo's head of research and development, has positioned AmorphOX as enabling both rapid systemic exposure for rescue medications and thermostable formulations for vaccines and biologics. That's a wide mandate for a platform still proving itself in human trials.
If OX640 advances to Phase 3, it will compete directly with ARS Pharma's neffy and Nasus Pharma's NS002 in the needle-free anaphylaxis market. ARS has first-mover advantage and is actively building payer coverage. Nasus reported faster early epinephrine exposure than EpiPen in interim Phase 2 data. Speed of onset, device usability, and stability profiles will likely differentiate products—assuming all reach approval. A crowded finish line.
OX124, the high-dose naloxone powder, illustrates regulatory complexity for combination products. Orexo submitted the NDA in mid-2023, and the FDA accepted it in November 2023 with a July 2024 decision date. The application was supported by pivotal study OX124-002, which demonstrated faster naloxone absorption versus an intramuscular reference.
Yet the July 2024 Complete Response Letter requested human-factors data and additional technical information without questioning efficacy. Device-constituent evaluation is a known FDA focus area, and guidance documents stress early human-factors work to avoid late-stage surprises. Orexo completed a new human-factors study and has been working toward resubmission, but the delay underscores that even strong pharmacokinetics can't overcome combination-product hurdles. Device design has become a regulatory gating factor as critical as drug safety.
The Competition Takes Different Paths
ARS Pharma's neffy is a liquid nasal spray, not a powder, and it secured approvals for both adult and pediatric doses within eight months. The company has built payer coverage and launched consumer campaigns around the tagline of needle-free relief, validating market demand. Whether powder formulations offer enough advantage over liquid sprays to displace an incumbent—especially one with marketing momentum—remains an open question.
Nasus Pharma uses Aptar's Unidose device for NS002 powder epinephrine and is also developing an intranasal naloxone powder. OptiNose's Exhalation Delivery System employs bi-directional airflow to improve deposition and has prior approval for a powder migraine treatment; the company is advancing fluticasone EDS for chronic rhinosinusitis. Aptar Pharma has collaborated with TFF Pharmaceuticals on thin-film-freezing powder vaccines delivered via Aptar's nasal device. Therakind offers DriDose dry-powder nasal platforms at research-and-development scale.
Each approach balances particle engineering, device mechanics, and manufacturing complexity differently. And each carries its own regulatory risk profile. Powder isn't inherently superior to liquid; it's a tradeoff that makes sense for certain clinical needs and fails to justify itself for others.
Federal Funding and Strategic Priorities
The government's willingness to bankroll OX390 development fits a broader trajectory. The FY2025 Presidential budget proposed $970 million for BARDA's advanced research and development, up $20 million, plus broader investments through the Administration for Strategic Preparedness and Response to strengthen domestic medical countermeasure production. BARDA's portfolio priorities include rapid-acting, thermostable products suitable for decentralized response and stockpiling.
Powder-based nasal delivery fits that mandate—if stability and usability data hold up under real-world conditions. And that's the qualifier that matters.
The overdose landscape is shifting, though not in ways that eliminate urgency. CDC provisional data for 2024 showed opioid-involved deaths declining materially versus 2023. Synthetic opioids other than methadone fell from approximately 72,800 to roughly 47,700; total opioid deaths dropped from around 79,400 to about 54,000. Age-adjusted rates followed the same trend. Media summaries cited year-over-year declines of 23 to 27 percent, with public health experts warning that progress remains fragile.
Fentanyl still drives the majority of fatalities, and adulterants complicate reversal efforts. The White House "Challenge to Save Lives from Overdose" enlisted more than 250 organizations—airlines, retailers, unions—to expand naloxone access, and federal agencies have implemented import controls on xylazine. The FDA warned clinicians in 2022 that naloxone may not reverse xylazine-driven respiratory depression, and bipartisan congressional bills in 2025 sought to schedule xylazine while preserving veterinary use.
The clinical rationale for complementary countermeasures like OX390 persists even as overall mortality trends downward. Maybe especially because the trends are improving—evidence that intervention works creates political will to fund the next generation of tools.
In anaphylaxis, the needle-free race is accelerating. ARS Pharma's neffy launch validated market demand and payer willingness to cover alternatives to auto-injectors. Powder candidates from Orexo and Nasus will compete on speed of onset, device ease-of-use, and room-temperature stability. Human-factors requirements will remain a gating factor. Device design must account for high-stress use by untrained bystanders, and taste or irritation issues can undermine adherence.
A 2024 review in Expert Opinion on Drug Delivery emphasized that dry-powder inhaler design should center on human factors to reduce critical errors, and those lessons likely apply to nasal powder devices. Perhaps more than formulators would like to admit.
Platform Adoption Beyond Rescue Medicine
Orexo's published stability data for peptides and biologics, if reproducible at commercial scale, position AmorphOX for business-development interest. The IQVIA Institute's 2025 R&D trends report noted that emerging biopharma originated 85 percent of the 48 U.S. new-active-substance launches in 2024, and R&D spending continues to grow. Delivery platforms that shorten development timelines or expand access into settings where cold chain is prohibitive should attract partnerships.
Amorphous solid dispersions for oral delivery have seen 48 FDA approvals over the past decade, proving that industry can scale complex formulation science. Intranasal powders for systemic delivery represent a narrower but strategically valuable niche. If Orexo—or competitors like Nasus, OptiNose, or TFF—can demonstrate versatility beyond emergency medicine, the technology could find applications in vaccines, peptide therapies, even oncology supportive care.
That's the big if. Laboratory bench work doesn't always survive the transition to commercial manufacturing, and regulatory expectations for combination products continue to tighten around human factors and device robustness.
The Remaining Challenges
Particle engineering must balance rapid dissolution against mucosal retention, excipients for permeation against irritation, and dose uniformity against device cost. Academic work on correlating in vitro release with in vivo pharmacokinetics is ongoing, but predictive models are not yet standardized. Every formulation still requires its own clinical validation.
Market-size estimates vary widely depending on how firms define the addressable opportunity—devices alone, total nasal therapies, or enabling technology across modalities. Investors should treat compound annual growth rates and total addressable market figures as directional signals rather than precise forecasts. The market-research firms are making educated guesses about a category still defining itself.
Regulatory pathways for combination products remain resource-intensive. The OX124 Complete Response Letter demonstrates that even strong efficacy data can't compensate for incomplete human-factors work or technical gaps
